EP1539931A4 - Agents de modulation de la differenciation et utilisations associees - Google Patents
Agents de modulation de la differenciation et utilisations associeesInfo
- Publication number
- EP1539931A4 EP1539931A4 EP03735152A EP03735152A EP1539931A4 EP 1539931 A4 EP1539931 A4 EP 1539931A4 EP 03735152 A EP03735152 A EP 03735152A EP 03735152 A EP03735152 A EP 03735152A EP 1539931 A4 EP1539931 A4 EP 1539931A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- modulating agents
- uses therefor
- differentiation modulating
- differentiation
- therefor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10184571A EP2267117A3 (fr) | 2002-06-27 | 2003-06-27 | Agents de modulation de la différentiation et leurs utilisations |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39213002P | 2002-06-27 | 2002-06-27 | |
US392130P | 2002-06-27 | ||
PCT/AU2003/000826 WO2004003179A1 (fr) | 2002-06-27 | 2003-06-27 | Agents de modulation de la differenciation et utilisations associees |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1539931A1 EP1539931A1 (fr) | 2005-06-15 |
EP1539931A4 true EP1539931A4 (fr) | 2006-08-23 |
Family
ID=30000816
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10184571A Withdrawn EP2267117A3 (fr) | 2002-06-27 | 2003-06-27 | Agents de modulation de la différentiation et leurs utilisations |
EP03735152A Withdrawn EP1539931A4 (fr) | 2002-06-27 | 2003-06-27 | Agents de modulation de la differenciation et utilisations associees |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10184571A Withdrawn EP2267117A3 (fr) | 2002-06-27 | 2003-06-27 | Agents de modulation de la différentiation et leurs utilisations |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP2267117A3 (fr) |
JP (2) | JP2005535629A (fr) |
CN (1) | CN1678734B (fr) |
AU (2) | AU2003236557B2 (fr) |
CA (1) | CA2490261A1 (fr) |
NZ (1) | NZ537208A (fr) |
WO (1) | WO2004003179A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2267117A3 (fr) * | 2002-06-27 | 2011-07-13 | Verva Pharmaceuticals Pty Ltd | Agents de modulation de la différentiation et leurs utilisations |
ATE506077T1 (de) * | 2003-10-16 | 2011-05-15 | Imclone Llc | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
JPWO2005093083A1 (ja) * | 2004-03-29 | 2008-02-14 | 和久 前田 | 疾病予測方法、及びその利用方法 |
US20090176306A1 (en) * | 2005-06-10 | 2009-07-09 | Toshio Taira | Method of inducing differentiation from visceral preadipocyte to visceral adipocyte |
GB0520063D0 (en) * | 2005-10-03 | 2005-11-09 | Novartis Forschungsstiftung | Methods for regulating metabolism and diagnosing disease |
US7946916B2 (en) | 2006-01-12 | 2011-05-24 | Waterleaf Ltd. | Variable payout wager games |
CN101058801B (zh) * | 2007-04-13 | 2010-05-19 | 中国人民解放军第二军医大学 | 促进人皮下脂肪干细胞分化成熟的方法及其应用 |
NZ584827A (en) | 2007-10-01 | 2012-10-26 | Isis Pharmaceuticals Inc | Antisense modulation of fibroblast growth factor receptor 4 expression |
CN101259266B (zh) * | 2008-04-14 | 2010-04-14 | 山东大学 | 一种前脂肪细胞异种疫苗及其制备方法和用途 |
US20130116171A1 (en) | 2010-04-16 | 2013-05-09 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf |
EP2721156B1 (fr) | 2011-06-16 | 2016-12-21 | Ionis Pharmaceuticals, Inc. | Modulation antisens de l'expression du récepteur 4 du facteur de croissance fibroblastique |
WO2013102209A1 (fr) | 2011-12-30 | 2013-07-04 | Joslin Diabetes Center, Inc. | Compositions à base de glypican-4 et procédés destinés au traitement et au diagnostic d'une résistance à l'insuline |
GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
AU2014255755B2 (en) | 2013-04-16 | 2018-10-25 | Orbsen Therapeutics Limited | Medical use of syndecan-2 |
WO2015061331A1 (fr) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Peptides de facteur de croissance des fibroblastes (fgf) 2/fgf1 chimériques et procédés d'utilisation |
EP3060238A4 (fr) | 2013-10-21 | 2017-06-07 | Salk Institute for Biological Studies | Facteur de croissance de fibroblaste 1 (fgf) muté et méthodes d'utilisation |
US20170065678A1 (en) * | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
JP6920207B2 (ja) | 2015-03-20 | 2021-08-18 | オルブセン セラピューティクス リミテッド | シンデカン−2のモジュレーターとその使用 |
WO2016172290A1 (fr) * | 2015-04-21 | 2016-10-27 | Salk Institute For Biological Studies | Procédés de traitement de la lipodystrophie à l'aide de composés fgf-1 |
AU2016344134A1 (en) | 2015-10-30 | 2018-05-31 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs |
WO2017122095A1 (fr) | 2016-01-15 | 2017-07-20 | Orbsen Therapeutics Limited | Compositions d'exosomes à base de sdc2 et leurs procédés d'isolement et d'utilisation |
WO2019012334A2 (fr) | 2017-07-14 | 2019-01-17 | Orbsen Therapeutics Limited | Procédés d'isolement et d'utilisation de cellules souches stromales cd39 |
US20210401728A1 (en) * | 2018-10-26 | 2021-12-30 | Ivan GALANIN | Topical Compositions and Methods to Promote Optimal Dermal White Adipose Tissue Composition in Vivo |
US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
EP4200019A1 (fr) | 2020-08-21 | 2023-06-28 | Genzyme Corporation | Anticorps anti-fgfr3 et méthodes d'utilisation |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0420081A1 (fr) * | 1989-09-26 | 1991-04-03 | Takeda Chemical Industries, Ltd. | Anticorps monoclonal contre la protéine FGF acide, sa production et utilisation |
WO2000071129A1 (fr) * | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazines inhibiteurs de kinases |
WO2001049849A1 (fr) * | 2000-01-05 | 2001-07-12 | Zymogenetics, Inc. | Zfgf11 : nouvel homologue de fgf |
WO2001070977A2 (fr) * | 2000-03-22 | 2001-09-27 | Amgen, Inc. | Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations |
EP1202065A1 (fr) * | 2000-10-25 | 2002-05-02 | Aventis Pharma S.A. | Le facteur de transcription NET de la famillie "TCF" comme régulateur de l'expression angiogénique |
WO2003099796A1 (fr) * | 2002-05-23 | 2003-12-04 | Cytopia Pty Ltd | Inhibiteurs de proteine kinase |
WO2004001059A2 (fr) * | 2002-06-20 | 2003-12-31 | Bristol-Myers Squibb Company | Inhibiteurs heterocycliques de kinases |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US424279A (en) | 1890-03-25 | Supporting wheel or pulley | ||
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4849338A (en) | 1982-07-16 | 1989-07-18 | Syntex (U.S.A.) Inc. | Simultaneous calibration heterogeneous immunoassay |
US4843000A (en) | 1979-12-26 | 1989-06-27 | Syntex (U.S.A.) Inc. | Simultaneous calibration heterogeneous immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5459276A (en) | 1994-05-20 | 1995-10-17 | Molecular Probes, Inc. | Benzazolylcoumarin-based ion indicators for heavy metals |
US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
US5405975A (en) | 1993-03-29 | 1995-04-11 | Molecular Probes, Inc. | Fluorescent ion-selective diaryldiaza crown ether conjugates |
US5227487A (en) | 1990-04-16 | 1993-07-13 | Molecular Probes, Inc. | Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes |
US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
US5453517A (en) | 1992-02-25 | 1995-09-26 | Molecular Probes, Inc. | Reactive derivatives of bapta used to make ion-selective chelators |
US5723218A (en) | 1990-04-16 | 1998-03-03 | Molecular Probes, Inc. | Dipyrrometheneboron difluoride labeled flourescent microparticles |
US5326692B1 (en) | 1992-05-13 | 1996-04-30 | Molecular Probes Inc | Fluorescent microparticles with controllable enhanced stokes shift |
US5648270A (en) | 1995-02-06 | 1997-07-15 | Molecular Probes, Inc. | Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles |
AU649066B2 (en) | 1990-07-25 | 1994-05-12 | Syngene, Inc. | Circular extension for generating multiple nucleic acid complements |
CA2118806A1 (fr) | 1991-09-18 | 1993-04-01 | William J. Dower | Methode pour la synthese de diverses series d'oligomeres |
US5422252A (en) | 1993-06-04 | 1995-06-06 | Becton, Dickinson And Company | Simultaneous amplification of multiple targets |
AU714486B2 (en) | 1995-11-21 | 2000-01-06 | Yale University | Unimolecular segment amplification and detection |
EP1071429B1 (fr) * | 1998-04-17 | 2002-01-30 | Trustees Of Tufts College | Inhibiteurs de la map kinase pour le traitement des maladies causees par la lipolyse induite par tnf-alpha |
US6153432A (en) * | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
EP1214409B1 (fr) * | 1999-09-08 | 2006-05-17 | Genentech, Inc. | Acides nucleiques et polypeptides du facteur 19 de croissance du fibroblaste, et procedes d'utilisation dans le traitement de l'obesite |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
AU5056501A (en) * | 2000-03-31 | 2001-10-08 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
EP2267117A3 (fr) * | 2002-06-27 | 2011-07-13 | Verva Pharmaceuticals Pty Ltd | Agents de modulation de la différentiation et leurs utilisations |
-
2003
- 2003-06-27 EP EP10184571A patent/EP2267117A3/fr not_active Withdrawn
- 2003-06-27 CN CN03820407XA patent/CN1678734B/zh not_active Expired - Fee Related
- 2003-06-27 WO PCT/AU2003/000826 patent/WO2004003179A1/fr active Application Filing
- 2003-06-27 CA CA002490261A patent/CA2490261A1/fr not_active Abandoned
- 2003-06-27 AU AU2003236557A patent/AU2003236557B2/en not_active Ceased
- 2003-06-27 EP EP03735152A patent/EP1539931A4/fr not_active Withdrawn
- 2003-06-27 JP JP2004516341A patent/JP2005535629A/ja active Pending
- 2003-06-27 NZ NZ537208A patent/NZ537208A/en not_active IP Right Cessation
-
2009
- 2009-12-24 AU AU2009251219A patent/AU2009251219B2/en not_active Ceased
-
2010
- 2010-05-06 JP JP2010106139A patent/JP2010215636A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0420081A1 (fr) * | 1989-09-26 | 1991-04-03 | Takeda Chemical Industries, Ltd. | Anticorps monoclonal contre la protéine FGF acide, sa production et utilisation |
WO2000071129A1 (fr) * | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazines inhibiteurs de kinases |
WO2001049849A1 (fr) * | 2000-01-05 | 2001-07-12 | Zymogenetics, Inc. | Zfgf11 : nouvel homologue de fgf |
WO2001070977A2 (fr) * | 2000-03-22 | 2001-09-27 | Amgen, Inc. | Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations |
EP1202065A1 (fr) * | 2000-10-25 | 2002-05-02 | Aventis Pharma S.A. | Le facteur de transcription NET de la famillie "TCF" comme régulateur de l'expression angiogénique |
WO2003099796A1 (fr) * | 2002-05-23 | 2003-12-04 | Cytopia Pty Ltd | Inhibiteurs de proteine kinase |
WO2004001059A2 (fr) * | 2002-06-20 | 2003-12-31 | Bristol-Myers Squibb Company | Inhibiteurs heterocycliques de kinases |
Non-Patent Citations (13)
Title |
---|
COSIC IRENA ET AL: "In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 130, no. 1, 1994, pages 1 - 9, XP009062598, ISSN: 0300-8177 * |
HAUNER H ET AL: "Effects of epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) on human adipocyte development and function.", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION FEB 1995, vol. 25, no. 2, February 1995 (1995-02-01), pages 90 - 96, XP000198734, ISSN: 0014-2972, DOI: 10.1111/j.1365-2362.1995.tb01532.x * |
KAWAGUCHI NOBUKO ET AL: "De novo adipogenesis in mice at the site of injection of basement membrane and basic fibroblast growth factor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 3, 3 February 1998 (1998-02-03), pages 1062 - 1066, XP002370034, ISSN: 0027-8424 * |
KRIEGER-BRAUER HEIDEMARIE I ET AL: "Antagonistic effects of different members of the fibroblast and platelet-derived growth factor families on adipose conversion and NADPH-dependent H-2O-2 generation in 3T3 L1-cells", BIOCHEMICAL JOURNAL, vol. 307, no. 2, 1995, pages 549 - 556, XP002370033, ISSN: 0264-6021 * |
MILLER ET AL: "Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice.", MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 6, 1 March 2000 (2000-03-01), pages 2260 - 2268, XP055072326, ISSN: 0270-7306 * |
ORNITZ D M ET AL: "RECEPTOR SPECIFICITY OF THE FIBROBLAST GROWTH FACTOR FAMILY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271, no. 25, 21 June 1996 (1996-06-21), pages 15292 - 15297, XP002919936, ISSN: 0021-9258, DOI: 10.1074/jbc.271.25.15292 * |
R. T. BOTTCHER ET AL: "Fibroblast Growth Factor Signaling during Early Vertebrate Development", ENDOCRINE REVIEWS, vol. 26, no. 1, 1 February 2005 (2005-02-01), pages 63 - 77, XP055072332, ISSN: 0163-769X, DOI: 10.1210/er.2003-0040 * |
RUSSELL T R ET AL: "CONVERSION OF 3T3 FIBROBLASTS INTO ADIPOSE CELLS: TRIGGERING OF DIFFERENTIATION BY PROSTAGLANDIN F2ALPHA AND I-METHYL-3-ISOBUTYL XANTHINE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 12, no. 73, 1 December 1976 (1976-12-01), pages 4516 - 4520, XP001079689, ISSN: 0027-8424, DOI: 10.1073/pnas.73.12.4516 * |
SASAKI K ET AL: "Actions of acidic fibroblast growth factor fragments on food intake in rats", OBESITY RESEARCH, BATON ROUGE, LA, US, vol. 3, no. Suppl 5, 1 December 1995 (1995-12-01), pages 697S - 706S, ISSN: 1071-7323 * |
SASAKI K ET AL: "EFFECTS OF FRIBROBLAST GROWTH FACTROS AND RELATED PEPTIDES ON FOOD INTAKE BY RATS", PHYSIOLOGY AND BEHAVIOR, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 56, no. 2, 1 January 1994 (1994-01-01), pages 211 - 218, XP000943197, ISSN: 0031-9384, DOI: 10.1016/0031-9384(94)90186-4 * |
SCHMIDT ET AL: "Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 26, 1 September 1990 (1990-09-01), pages 15489 - 15495, XP055072329, ISSN: 0021-9258 * |
See also references of WO2004003179A1 * |
SERRERO G ET AL: "Prostaglandin F2 alpha inhibits epidermal growth factor binding to cellular receptors on adipocyte precursors in primary culture", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 212, no. 3, 26 July 1995 (1995-07-26), pages 1125 - 1132, XP008081146, ISSN: 0006-291X, DOI: 10.1006/bbrc.1995.2085 * |
Also Published As
Publication number | Publication date |
---|---|
CN1678734A (zh) | 2005-10-05 |
NZ537208A (en) | 2009-02-28 |
CA2490261A1 (fr) | 2004-01-08 |
AU2003236557B2 (en) | 2009-10-01 |
EP2267117A3 (fr) | 2011-07-13 |
JP2005535629A (ja) | 2005-11-24 |
CN1678734B (zh) | 2012-12-12 |
EP2267117A2 (fr) | 2010-12-29 |
EP1539931A1 (fr) | 2005-06-15 |
AU2009251219B2 (en) | 2013-01-10 |
JP2010215636A (ja) | 2010-09-30 |
AU2003236557A1 (en) | 2004-01-19 |
AU2009251219A1 (en) | 2010-01-28 |
WO2004003179A1 (fr) | 2004-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1539931A4 (fr) | Agents de modulation de la differenciation et utilisations associees | |
EP1539941A4 (fr) | Adzymes et leurs utilisations | |
PT2702871T (pt) | Biotecido de colagénio e sua utilização | |
GB2384570B (en) | Modulators | |
EP1501544A4 (fr) | Alcam et modulateurs d'alcam | |
IL154553A0 (en) | Urocortin-iii and uses thereof | |
GB0220214D0 (en) | Compounds and their use | |
SI1551805T1 (sl) | Substituirani gama-fenil-delta-laktami in njihova uporaba | |
AU2003232075A8 (en) | Modified t lymphocytes and uses therefor | |
GB0126889D0 (en) | Compounds and their uses | |
IL165112A0 (en) | Variant integrinpolypeptides and thereof | |
AU2002364612A8 (en) | Methods and materials for modulating enac-beta | |
AU2003298739A8 (en) | Intermedin and its uses | |
AU2003231827A8 (en) | Pseudo-tissues and uses thereof | |
GB0102717D0 (en) | Cells and uses therefor | |
AU2003209879A8 (en) | Vpr modulators and uses thereof | |
AU2003302173A8 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
AU2003228397A8 (en) | Hausp-p53 interaction and uses thereof | |
AU2003216442A8 (en) | Enkurin and uses thereof | |
AU2003228990A8 (en) | Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators | |
GB0218031D0 (en) | Compounds and their use | |
AU2003255232A1 (en) | Antigiardial agents and use thereof | |
AU2004900050A0 (en) | Differentiation modulating agents and uses therefor | |
AU2002367320A8 (en) | Methods and materials for modulating task-3 | |
GB0208672D0 (en) | Integrated mach-zehnder modulator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050127 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076838 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060725 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ADIPOGEN PHARMACEUTICALS PTY LIMITED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ADIPOGEN PHARMACEUTICALS PTY LIMITED |
|
17Q | First examination report despatched |
Effective date: 20090902 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VERVA PHARMACEUTICALS PTY |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/18 20060101ALI20130703BHEP Ipc: A61K 38/18 20060101AFI20130703BHEP Ipc: C12N 5/077 20100101ALI20130703BHEP Ipc: G01N 33/74 20060101ALI20130703BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1076838 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140103 |